The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV — a move the ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

The FDA approved Gilead’s landmark long-acting HIV treatment lenacapavir Wednesday afternoon. The drug will be marketed under ...

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

The FDA on Wednesday approved a highly effective long-acting shot for HIV prevention that is administered just twice per year ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

The recent approval of lenacapavir could change the way that clinicians approach both treating and preventing HIV in those at risk, as long as the treatment can get into their hands.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections ...